Fig. 8
From: Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice
The biological stability and pharmacokinetics study of PEGylated FGF21 in DIO mice. Pharmacokinetic profiles of FGF21 and PEG-FGF21. DIO mice were injected intravenously with 25 μg/kg FGF21 and PEG-FGF21 and then blood samples were collected at the indicated time points. The concentration of FGF21 was measured using the human FGF21 immunoassay ELISA Kit(a); The concentrations of FGF21 and PEG-FGF21 in kidney were compared by FGF21/Total protein after treatment for 2 months (b)